Vendor source

Reviewed 8 Oct 2026

Completeness Strong (72%)

ProFound AI Risk

iCAD

ProFound AI risk is a clinical decision support tool that provides personalized one-, two-, and three-year breast cancer risk estimates based on 2D screening mammograms or 3D breast tomosynthesis. ProFound AI Risk combines a range of risk factors (age, density, subtle mammographic features) to produce short-term risk assessments that physicians can use to create customized screening plans and catch early-stage cancers.

Supported by 6 papers

Key Features

  • Individual 1y/2y/3y breast cancer risk score

General Information

Product name

ProFound AI Risk

Company

Modality

Mammography

Main task

Not specified

Subspeciality

Breast

Disease targeted

Breast cancer

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class I

Verified by Health AI Register

Other certifications

Not specified

Technical Specifications

Patient population age

Not specified

Input

2D Mammography, 3D Digital Breast Tomosynthesis, age of patient

Input format

DICOM

Output

Risk score

Output format

DICOM SR, GSPS

Integration

Integration in standard reading environment (PACS), Stand-alone third party application

Deployment

Locally on dedicated hardware

Trigger for analysis

Automatically, right after the image acquisition

Processing time

1 - 10 minutes

Population

Asymptomatic screening population

Market Presence

On market since

07-2020

AI Platforms

Blackford Analysis, CARPL.AI, deepc, Philips Healthcare, Sectra

Resellers

Icad inc, RMS Medical Devices

Countries present

-

Paying clinical customers

>1

Research/test users

>1

Pricing Information

Pricing model

Not specified

Based on

Not specified

Source: Vendor | First published: Dec 19, 2023 | Last updated: Oct 8, 2026